STOCK TITAN

Citius Pharmaceuticals Inc - CTXR STOCK NEWS

Welcome to our dedicated page for Citius Pharmaceuticals news (Ticker: CTXR), a resource for investors and traders seeking the latest updates and insights on Citius Pharmaceuticals stock.

Overview

Citius Pharmaceuticals Inc. (CTXR) is a dynamic biopharmaceutical company dedicated to the development and commercialization of first‐in‐class critical care products. Specializing in innovative therapies across multiple healthcare segments, the company focuses on addressing unmet medical needs with novel solutions in the fields of anti-infectives, oncology, prescription pharmacotherapy, and stem cell therapies. With a clinical portfolio featuring targeted immunotherapies for conditions like cutaneous T-cell lymphoma (CTCL) and advanced anti-infective products for the management of catheter-related infections, Citius Pharmaceuticals operates at the intersection of cutting-edge biomedical research and critical care innovation.

From its early-stage beginnings to its current position as a pivotal player in the critical care market, Citius Pharmaceuticals has built its business model around breakthrough science and rigorous clinical development. By harnessing the potential of recombinant fusion proteins and novel formulations, the company is designing therapies with unique mechanisms of action – for example, its IL-2 receptor-targeted immunotherapy that aims to selectively eliminate malignant T-cells while modulating immune responses. Such innovative approaches underscore its commitment to both scientific excellence and clinical relevance.

Core Product Pipeline

The company’s product pipeline is extensive and multifaceted. Key programs include:

  • LYMPHIR™ (denileukin diftitox-cxdl): A targeted immunotherapy approved by the FDA for the treatment of relapsed or refractory CTCL after prior systemic therapy. This therapy uniquely targets the interleukin-2 (IL-2) receptor and represents a novel treatment option by both directly killing malignant cells and modulating the immune environment.
  • Mino-Lok®: An antibiotic lock solution designed to salvage catheters in patients suffering from catheter-related bloodstream infections. This product, developed using a liquefying gel-based formulation, demonstrates the company’s commitment to reducing complications associated with invasive medical devices.
  • Halo-Lido (CITI-002): A topical formulation combining corticosteroid-lidocaine components intended to provide anti-inflammatory and anesthetic relief. Developed primarily for conditions such as hemorrhoids, this product is formulated to offer symptomatic relief while avoiding cumulative toxicity.
  • Stem Cell Therapy Candidate: Focused on mesenchymal stem cell applications for critical care indications, this candidate highlights the company’s investment in advanced regenerative medicine as part of its broader commitment to innovative therapeutic solutions.

Market Position and Clinical Excellence

Citius Pharmaceuticals operates within a highly specialized niche in the biopharmaceutical industry, where robust clinical evidence, regulatory compliance, and strategic innovation converge. The company has successfully navigated complex clinical trials, regulatory submissions, and strategic mergers, enabling it to concentrate its core expertise on high-impact therapies in critical care. Recent milestones, such as achieving FDA approval for LYMPHIR and meeting key endpoints in Phase 3 trials for Mino-Lok, have reinforced its competitive standing and underscored its scientific rigor.

Notably, the company’s emphasis on critical care products reflects an understanding that many patients with severe, life‐threatening conditions require targeted, rapid-acting therapies that address both symptoms and underlying pathologies. By using advanced molecular techniques and leveraging innovative clinical trial designs, Citius Pharmaceuticals demonstrates an informed approach to drug development that prioritizes patient safety and clinical efficacy.

Operational Strategy and Strategic Developments

The operational blueprint of Citius Pharmaceuticals is characterized by its integrated R&D strategy, comprehensive clinical evaluation, and strategic capital allocation. Coupled with a recent merger that enabled the creation of a dedicated oncology subsidiary, the company is poised to better leverage market opportunities, streamline clinical commercialization, and ensure that its innovative therapies reach the patients who need them most. The company works closely with regulatory authorities, adhering to stringent guidelines and continuously engaging in clinical research dialogues, ensuring that its therapeutic candidates meet high standards of safety and efficacy.

This approach is indicative of the company’s broader mission: to transform critical care through the delivery of innovative, clinically validated products that address significant unmet needs. Its product development is informed by rigorous preclinical research, robust clinical trial data, and precise regulatory strategy, which together create a framework that speaks to the company’s expertise and trustworthiness in the biopharmaceutical space.

Conclusion

In summary, Citius Pharmaceuticals Inc. stands out as a biopharmaceutical innovator in the critical care market. Through a robust and diversified pipeline that includes breakthrough immunotherapy for CTCL, advanced antimicrobial solutions for catheter-related infections, and novel formulations for pain and inflammation management, the company continues to demonstrate its commitment to clinical excellence and scientific innovation. Its deep industry expertise, commitment to regulatory compliance, and strategic focus on high-need therapeutic areas position it uniquely within its competitive landscape.

Rhea-AI Summary

Citius Pharmaceuticals (NASDAQ: CTXR) has announced a $2 million registered direct offering of common stock. The company will issue 1,739,131 shares at a purchase price of $1.15 per share, with the option for pre-funded warrants. The offering, expected to close around April 2, 2025, is being facilitated by H.C. Wainwright & Co. as the exclusive placement agent.

The net proceeds, after deducting placement agent fees and offering expenses, will be used to support the commercial launch of LYMPHIR™ and general corporate purposes. The offering is being made through a shelf registration statement filed with the SEC on February 23, 2024, and declared effective on March 1, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.46%
Tags
-
Rhea-AI Summary

Citius Pharmaceuticals (CTXR) reported its fiscal Q1 2025 results, highlighting preparations for the LYMPHIR commercial launch in H1 2025. The company secured a new J-code (J9161) for LYMPHIR, effective April 1, 2025, and reported promising preliminary results from an ongoing Phase I trial combining LYMPHIR with pembrolizumab.

Financial results showed cash and cash equivalents of $1.1 million as of December 31, 2024. The company reported a net loss of $10.3 million ($1.30 per share), compared to $9.2 million ($1.45 per share) in the prior year. R&D expenses decreased to $2.1 million from $2.6 million, while G&A expenses increased to $5.4 million from $3.7 million.

The company raised $6.5 million through offerings in late 2024 and early 2025, completed a 1-for-25 reverse stock split, and regained Nasdaq compliance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.18%
Tags
-
Rhea-AI Summary

Citius Pharmaceuticals and Citius Oncology announced that LYMPHIR™ (denileukin diftitox-cxdl) has received a permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J9161) from the Centers for Medicare & Medicaid Services. The code will be effective April 1, 2025.

LYMPHIR is FDA-approved for treating adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The permanent J-code will help streamline billing and reimbursement processes for healthcare providers administering LYMPHIR, facilitating access for patients with commercial and government insurance coverage.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Citius Pharmaceuticals (Nasdaq: CTXR) announced a registered direct offering priced at-the-market under Nasdaq rules. The company has entered into definitive agreements to sell 743,496 shares of its common stock along with warrants to purchase an equal number of shares. The purchase price is $4.035 per share and accompanying warrant.

The warrants have an exercise price of $3.91 per share, are exercisable immediately upon issuance, and will expire five years from the initial exercise date. The offering is expected to close around January 8, 2025, subject to customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering.

The aggregate gross proceeds are anticipated to be approximately $3 million, before deducting placement agent fees and other expenses. Citius plans to use the net proceeds for general corporate purposes, including pre-clinical and clinical development, working capital, and capital expenditures.

The securities are being offered under a shelf registration statement filed with the SEC on February 23, 2024 and declared effective on March 1, 2024. The offering will be made by a prospectus and prospectus supplement available on the SEC's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.1%
Tags
-
Rhea-AI Summary

Citius Pharmaceuticals and its subsidiary Citius Oncology announced preparations for the commercial launch of LYMPHIR™ in the first half of 2025. LYMPHIR, approved in August 2024, is an immunotherapy treatment for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL).

The companies have made significant progress in key launch areas including: securing commercial supply agreements and producing first-year launch supply; implementing healthcare provider education programs; working on reimbursement pathways; submitting for a unique J-code; securing inclusion in NCCN guidelines; developing patient assistance programs; and building a specialized sales team.

Management is also exploring additional growth opportunities through international licensing partnerships and potential expanded indications for LYMPHIR, including its use as a combination immunotherapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
none
-
Rhea-AI Summary

Citius Oncology (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (Nasdaq: CTXR), has engaged Jefferies as its exclusive financial advisor to explore strategic alternatives for maximizing shareholder value. The company is considering various options including partnerships, joint ventures, mergers, acquisitions, and licensing transactions.

The announcement comes as Citius Oncology prepares to launch LYMPHIR™, their recently FDA-approved therapy for treating patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) who have undergone at least one prior systemic therapy.

The company has not established a specific timeline for this strategic review process and will only disclose developments if the Board of Directors approves a specific transaction or deems disclosure necessary. There is no guarantee that this process will result in any strategic transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
none
Rhea-AI Summary

Citius Pharmaceuticals (CTXR) reported fiscal year 2024 results, highlighting key achievements including FDA approval of LYMPHIR™ for CTCL treatment and positive Phase 3 trial results for Mino-Lok®. The company reported cash and equivalents of $3.3 million as of September 30, 2024. Financial results show R&D expenses decreased to $11.9 million from $14.8 million, while G&A expenses increased to $18.2 million from $15.3 million. Net loss widened to $39.4 million ($5.97 per share) compared to $32.5 million ($5.57 per share) in 2023. The company completed merger of its oncology subsidiary to form Citius Oncology (CTOR) and plans LYMPHIR commercial launch in first half of 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
-
Rhea-AI Summary

Citius Pharmaceuticals announced a productive Type C meeting with the FDA following the successful completion of their Phase 3 clinical trial for Mino-Lok®. The meeting focused on discussing clinical trial data and establishing a pathway for future New Drug Application (NDA) submission. The FDA provided clear and actionable guidance regarding the novel catheter lock solution designed to salvage central venous catheters in patients with bloodstream infections. The company reports that Mino-Lok® demonstrated compelling clinical outcomes in Phase 3, potentially offering an alternative to catheter removal that could reduce healthcare costs and improve patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
-
Rhea-AI Summary

Citius Pharmaceuticals announced a 1-for-25 reverse stock split effective November 25, 2024, with split-adjusted trading beginning November 26 under the symbol CTXR. The split aims to regain Nasdaq compliance by increasing the share price above the $1.00 minimum bid requirement. The action will reduce authorized shares from 400 million to 16 million, and outstanding shares from approximately 193 million to 7.7 million. No fractional shares will be issued, with rounding up to the nearest whole share. The split will also affect outstanding warrants and stock options, with proportionate adjustments to exercise prices.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.96%
Tags
Rhea-AI Summary

Citius Pharmaceuticals (Nasdaq: CTXR) has closed a $3 million registered direct offering, selling 12,000,000 shares of common stock with accompanying warrants at $0.25 per share and warrant. The warrants are immediately exercisable at $0.25 per share and expire in five years. H.C. Wainwright & Co. served as the exclusive placement agent. The company plans to use the net proceeds for general corporate purposes, including pre-clinical and clinical development of product candidates, working capital, and capital expenditures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.1%
Tags

FAQ

What is the current stock price of Citius Pharmaceuticals (CTXR)?

The current stock price of Citius Pharmaceuticals (CTXR) is $1.015 as of April 4, 2025.

What is the market cap of Citius Pharmaceuticals (CTXR)?

The market cap of Citius Pharmaceuticals (CTXR) is approximately 8.7M.

What is the primary focus of Citius Pharmaceuticals Inc.?

Citius Pharmaceuticals focuses on developing and commercializing first-in-class critical care products. Their portfolio includes innovative therapies in areas like anti-infectives, oncology, prescription products, and stem cell treatments.

Which therapeutic areas are covered by their product pipeline?

The company’s pipeline spans multiple therapeutic areas, including targeted immunotherapy for cutaneous T-cell lymphoma, antibiotic solutions for catheter-related infections, topical formulations for inflammatory conditions, and stem cell therapies for critical care applications.

What distinguishes LYMPHIR™ from other CTCL treatments?

LYMPHIR™ is distinguished by its targeted mechanism; it binds to IL-2 receptors on malignant T-cells and regulatory T-cells to induce cell death while modulating the immune response. This unique action offers a novel treatment approach for patients with relapsed or refractory CTCL.

How does Citius Pharmaceuticals ensure clinical excellence?

The company engages in rigorous clinical trials to validate the safety and efficacy of its products. It works closely with regulatory bodies like the FDA and incorporates advanced trial designs and robust scientific methodologies to build a strong clinical evidence base.

What role does innovation play in Citius Pharmaceuticals' business model?

Innovation is central to the company’s strategy. By leveraging advanced biotechnology platforms and novel drug formulations, Citius Pharmaceuticals is able to address complex medical needs through breakthrough therapies that differentiate it in the competitive biopharmaceutical landscape.

How is the company positioned within the competitive landscape?

Citius Pharmaceuticals is uniquely positioned as a specialist in critical care products. Its differentiated approach, marked by unique mechanisms such as IL-2 receptor targeting and a diversified portfolio of therapies, enables it to compete effectively in niche markets with high unmet needs.

What are some key milestones achieved by the company?

Key milestones include the FDA approval of LYMPHIR™ for CTCL, successful completion of pivotal trials for the Mino-Lok antibiotic lock solution, and strategic mergers that have enhanced its focus on targeted oncology therapies. These achievements underscore its commitment to clinical innovation and regulatory compliance.

What strategic initiatives support its product commercialization?

The company’s strategic initiatives include comprehensive clinical research, strong regulatory engagement, and careful capital allocation. Recent mergers and the spin-off of its oncology subsidiary further enhance its focus on commercializing innovative therapies and ensuring that they reach patients efficiently.
Citius Pharmaceuticals Inc

Nasdaq:CTXR

CTXR Rankings

CTXR Stock Data

8.68M
8.40M
5.74%
7.97%
6.37%
Biotechnology
Pharmaceutical Preparations
Link
United States
CRANFORD